UROwebinar: Standardised PSMA PET Analysis and Reporting Consensus (SPARC) and radioligand treatment in prostate cancer

This webinar aims to highlight the elements and rationale of the recent Standardised PSMA PET Analysis and Reporting Consensus (SPARC) initiative.

PSMA PET is playing an increasingly important role in the management of prostate cancer. However, there is a clear need for the standardised reading and reporting of PSMA PET to ensure information transfer from nuclear medicine to clinicians.

In this UROwebinar, the experts will present the identified SPARC standards and case examples to enhance understanding. Moreover, the definitions of disease progression based on PSMA-PET are unclear. The prostate cancer working group 4 (PCWG 4) recommendations are now finalised and the UROwebinar will highlight areas of alignment between both approaches.

Furthermore, the UROwebinar will offer valuable insights of a PCa patient, who received the proper treatment thanks to the PSMA PET. He was not treated with radioligand therapy.

The UROwebinar will also demonstrate how reimbursement and treatment availability directly shape patient access across Europe. The experts will compare centre maturity and national reimbursement pathways through the perspective of healthcare professionals.